- Integral Diagnostics (IDX) raises $47 million from a retail entitlement offer to fund its acquisition of Peloton Radiology
- A total of 13.6 million new shares will be issued at a price of $3.44 each
- The new shares will rank equally to existing shares, but will not be eligible for the upcoming interim dividend
- Shares close 2.07 per cent lower today at $3.79 each
Integral Diagnostics (IDX) has raised $47 million from a retail entitlement offer to fund its acquisition of Peloton Radiology.
A total of 6.6 million new shares were issued to eligible retail shareholders at $3.44 each, raising $22.8 million. This represents a total take up rate of 49 per cent.
About seven million shares, which were not taken up by eligible retail shareholders will be allocated to sub-underwriters of the entitlement offer.
The new shares issued will rank equally to existing shares but will not be eligible for the upcoming interim dividend.
They will be issued on Monday next week with trading on the ASX to commence on Tuesday.
The retail component follows the successful completion of the institutional component, which raised an additional $43 million.
“We are extremely pleased with the strong support received from our shareholders in response to the entitlement offer and acquisition of Peloton Radiology. We thank our investors for their continued support of IDX,” Managing Director and CEO Dr Ian Kadish said.
Shares closed 2.07 per cent lower today at $3.79 each.